These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 19603168

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Axitinib plasma pharmacokinetics and ethnic differences.
    Chen Y, Suzuki A, Tortorici MA, Garrett M, LaBadie RR, Umeyama Y, Pithavala YK.
    Invest New Drugs; 2015 Apr; 33(2):521-32. PubMed ID: 25663295
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetic analysis of axitinib in healthy volunteers.
    Garrett M, Poland B, Brennan M, Hee B, Pithavala YK, Amantea MA.
    Br J Clin Pharmacol; 2014 Mar; 77(3):480-92. PubMed ID: 23834452
    [Abstract] [Full Text] [Related]

  • 5. Clinical pharmacology of axitinib.
    Chen Y, Tortorici MA, Garrett M, Hee B, Klamerus KJ, Pithavala YK.
    Clin Pharmacokinet; 2013 Sep; 52(9):713-25. PubMed ID: 23677771
    [Abstract] [Full Text] [Related]

  • 6. Meta-analysis of contribution of genetic polymorphisms in drug-metabolizing enzymes or transporters to axitinib pharmacokinetics.
    Brennan M, Williams JA, Chen Y, Tortorici M, Pithavala Y, Liu YC.
    Eur J Clin Pharmacol; 2012 May; 68(5):645-55. PubMed ID: 22170007
    [Abstract] [Full Text] [Related]

  • 7. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects.
    Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D.
    Clin Pharmacol Drug Dev; 2015 Sep; 4(5):354-60. PubMed ID: 27137144
    [Abstract] [Full Text] [Related]

  • 8. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants.
    Li J, Rockich K, Yuska B, Zhou G, Epstein N, Punwani N, Chen X, Yeleswaram S.
    J Clin Pharmacol; 2020 Nov; 60(11):1519-1526. PubMed ID: 32515832
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
    Rini BI, Garrett M, Poland B, Dutcher JP, Rixe O, Wilding G, Stadler WM, Pithavala YK, Kim S, Tarazi J, Motzer RJ.
    J Clin Pharmacol; 2013 May; 53(5):491-504. PubMed ID: 23553560
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
    Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP.
    Cancer Chemother Pharmacol; 2014 Dec; 74(6):1279-89. PubMed ID: 25336084
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers.
    Pithavala YK, Chen Y, Toh M, Selaru P, LaBadie RR, Garrett M, Hee B, Mount J, Ni G, Klamerus KJ, Tortorici MA.
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):103-12. PubMed ID: 22644797
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
    Shaik MN, Hee B, Wei H, LaBadie RR.
    Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
    Zahir H, Greenberg J, Shuster D, Hsu C, Watanabe K, LaCreta F.
    Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
    [Abstract] [Full Text] [Related]

  • 20. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.
    Fujiwara Y, Kiyota N, Chayahara N, Suzuki A, Umeyama Y, Mukohara T, Minami H.
    Invest New Drugs; 2012 Jun; 30(3):1055-64. PubMed ID: 21301929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.